Status:
TERMINATED
A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease
Lead Sponsor:
Pfizer
Conditions:
Coronary Disease
Diabetes Mellitus
Eligibility:
All Genders
45-75 years
Phase:
PHASE3
Brief Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To demonstrate if torcetrapib/atorvastatin can reduce the risk for major cardiovascular disease events, when compare...
Eligibility Criteria
Inclusion
- Diagnosis of coronary heart disease or risk equivalents that place the patient at high risk for cardiovascular disease events
Exclusion
- Women who are pregnant or lactating, or planning to become pregnant.
- Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid
- Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
- Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluationof response, or render unlikely that the subject would complete the study
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
15067 Patients enrolled
Trial Details
Trial ID
NCT00134264
Start Date
July 1 2004
End Date
June 1 2007
Last Update
February 3 2012
Active Locations (221)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Alabaster, Alabama, United States
2
Pfizer Investigational Site
Birmingham, Alabama, United States
3
Pfizer Investigational Site
Gilbert, Arizona, United States
4
Pfizer Investigational Site
Phoenix, Arizona, United States